12 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27171036	164	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.	University Of Nebraska Medical Center
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School Of Medicine At Mount Sinai
23600925	12	Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.	H. Lee Moffitt Cancer Center And Research Institute
20138512	82	Discovery of potent and bioavailable GSK-3beta inhibitors.	Roche Palo Alto
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
19338355	104	From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.	University Of Illinois At Chicago
21985426	27	Chromone containing sulfonamides as potent carbonic anhydrase inhibitors.	Ondokuz Mayis University
17964169	24	Synthesis, nicotinic acetylcholine receptor binding, and pharmacological properties of 3'-(substituted phenyl)deschloroepibatidine analogs.	Research Triangle Institute
16242653	33	A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression.	Gpc Biotech